دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change
Tiffany H Taft, PsyD, MIS, Josie McGarva, BS, Tina A Omprakash, BS, Kathryn Tomasino, PhD, Anjali Pandit, PhD, Ece A Mutlu, MD, Stephen B Hanauer, MD
doi : 10.1093/ibd/izac148
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 675–683
Medical trauma related to IBD (IBD-PTS) affects approximately 25% of patients and is associated with poor outcomes. Prior studies identify common hospitalization experiences as potentially traumatic but have not measured risk relationships for the development of IBD-PTS. We aim to investigate what aspects of hospitalizations may increase the chance of medical trauma and IBD-PTS development.
Sustained Diet-Induced Remission in Pediatric Crohn’s Disease Is Associated With Kynurenine and Serotonin Pathways
Mohammed Ghiboub, PhD, Rotem Sigall Boneh, RD, Bruno Sovran, PhD, Eytan Wine, MD, PhD, Antoine Lefèvre, Patrick Emond, PharmD, PhD, Charlotte M Verburgt, MD, Marc A Benninga, MD, PhD, Wouter J de Jonge, PhD, Johan E Van Limbergen, MD, PhD
doi : 10.1093/ibd/izac262
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 684–694,
Both the Crohn’s disease exclusion diet combined with partial enteral nutrition (CDED+PEN) and exclusive enteral nutrition (EEN) can induce remission in mild-to-moderate pediatric Crohn’s disease and are associated with a marked decrease in fecal kynurenine levels. This suggests a link between clinical outcome of dietary therapy and changes in tryptophan metabolism pathways. Here
Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis
William Yuan, PhD, Jayson S Marwaha, MD, Shana T Rakowsky, MD, Nathan P Palmer, PhD, Isaac S Kohane, MD PhD, David T Rubin, MD, Gabriel A Brat, MD MPH, Joseph D Feuerstein, MD
doi : 10.1093/ibd/izac134
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 695–704
With an increasing number of therapeutic options available for the management of ulcerative colitis (UC), the variability in treatment and prescribing patterns is not well known. While recent guidelines have provided updates on how these therapeutic options should be used, patterns of long-term use of these drugs over the past 2 decades remain unclear.
A Systematic Review of Crohn’s Disease Case Definitions in Administrative or Claims Databases
Susan Hutfless, PhD, Ryan A Jasper, Aman Tilak, MBBS, Tamoghna Ghosh, MBBS, Saurabh Kedia, MBBS, Simon Liu, BS, Nathalie H Urrunaga, MD, MS, Matthew Josephson, MD, Arshit Narang, MBBS, Steve Miller, MD, MBE, Po-Hung Chen, MD, Shelly Joseph, MD, Steven R Brant, MD
doi : 10.1093/ibd/izac131
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 705–715
We sought to review Crohn’s disease (CD) case definitions that use diagnosis, procedure, and medication claims.
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn’s Disease
Neeraj Narula, MD, MPH, FRCPC, Emily C L Wong, BHSc, Parambir S Dulai, MD, John K Marshall, MD, MSc, FRCPC, Vipul Jairath, MD, PhD, FRCPC, Walter Reinisch, MD, PhD
doi : 10.1093/ibd/izac130
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 716–725
We compared the Simple Endoscopic Score for Crohn’s Disease (SES-CD) and Modified Multiplied SES-CD (MM-SES-CD) scores with the Rutgeerts score for predicting clinical recurrence (CR) of postoperative Crohn’s disease (CD).
Primary Care Professionals’ Attitudes Towards Vaccination Recommendation for Patients With Inflammatory Bowel Disease
Fang Xu, PhD, Neal deJong, MD, Michael D Kappelman, MD, Kurt J Greenlund, PhD, Susan A Carlson, PhD
doi : 10.1093/ibd/izac129
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 726–734
Immunization among patients with inflammatory bowel disease (IBD) is suboptimal. We sought to characterize attitudes of US primary care professionals (PCPs) towards immunization practices for patients with IBD.
Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019
Jeff Y Yang, MSPH, Jennifer L Lund, PhD, Virginia Pate, MS, Michael D Kappelman, MD, MPH
doi : 10.1093/ibd/izac136
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 735–743
Evaluation of mucosal healing with colonoscopy is recommended for inflammatory bowel disease (IBD) management; however, little is known about real-world use of treat-to-target monitoring following IBD treatment initiation. We aimed to estimate the proportion of U.S. commercially insured IBD patients who receive colonoscopy in the 3 to 15 months after initiating treatment.
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
Edward V Loftus, Jr, MD, Daniel C Baumgart, MD, Krisztina Gecse, MD, Jami A Kinnucan, MD, Susan B Connelly, PharmD, Leonardo Salese, MD, Chinyu Su, MD, Kenneth K Kwok, MS, John C Woolcott, PhD, Alessandro Armuzzi, MD
doi : 10.1093/ibd/izac139
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 744–751
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Patients with inflammatory bowel disease are susceptible to Clostridium difficile infection (CDI). Here, we evaluate CDI in the tofacitinib UC clinical program.
Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries
Przemysław Holko, PhD, Paweł Kawalec, PhD, Prof, Magdalena Sajak-Szczerba, MSc, Luisa Avedano, MSc, Małgorzata Mossakowska, PhD
doi : 10.1093/ibd/izac144
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 752–762
National studies report a high variability of indirect costs of inflammatory bowel disease (IBD). In this study, selected aspects of the societal burden of IBDs were compared between 12 European countries.
Examination Under Anesthesia May Not Be Universally Required Prior to Anti-TNF Therapy in Perianal Crohn’s Disease: A Comparative Cohort Study
Melissa Chan, MBBS, Moses Fung, MD, Kevin Chin Koon Siw, MDCM, Reena Khanna, MD, MSc, Anthony de Buck van Overstraeten, MD, MSc, Elham Sabri, MSc, Jeffrey D McCurdy, MD, PhD
doi : 10.1093/ibd/izac143
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 763–770
Multidisciplinary care involving exam under anesthesia (EUA) and tumor necrosis factor (TNF) inhibitors is recommended for perianal Crohn’s disease. However, the impact of this combined approach is not well established.
The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms
Jing Wang, PhD, Michael Macoritto, PhD, Heath Guay, PhD, Justin W Davis, PhD, Marc C Levesque, MD, PhD, Xiaohong Cao, PhD
doi : 10.1093/ibd/izac246
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 771–782
Janus kinase (JAK) 1 inhibitor upadacitinib and IL-23 inhibitor risankizumab are efficacious in inflammatory bowel disease (IBD) patients who are antitumor necrosis factor (anti-TNF)-α inadequate responders (TNF-IRs). We aimed to understand the mechanisms mediating the response of upadacitinib and risankizumab.
Histones of Neutrophil Extracellular Traps Directly Disrupt the Permeability and Integrity of the Intestinal Epithelial Barrier
Hsuan-Ju Lai, MS, Ha T Doan, MD, Elliot Y Lin, MS, Yi-Ling Chiu, BS, Yuan-Kai Cheng, MS, Yi-He Lin, MS, Hao-Sen Chiang, PhD
doi : 10.1093/ibd/izac256
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 783–797
Increased neutrophil extracellular trap (NET) formation and abundant NET-associated proteins are frequently found in the inflamed colon of patients with inflammatory bowel disease. Peptidyl arginine deiminase 4 (PAD4) activation is essential for the generation of NET and NET-mediated pathogenesis.
Epicutaneous Immunotherapy with CBir1 Alleviates Intestinal Inflammation
Xin Chen, PhD, Charles O Elson, MD, David Dunkin, MD
doi : 10.1093/ibd/izac261
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 798–807
Inflammatory bowel disease may be due to failed tolerance to normal gut bacteria. We demonstrate that epicutaneous immunotherapy (ET) to ovalbumin can alleviate colitis in murine models. However, most people are tolerant to or have anergy to ovalbumin. Half of Crohn’s disease (CD) patients have CBir1 antibodies that can be elevated years before CD development. We determined whether ET with a CBir1 multi-epitope peptide (MEP1) could alleviate colitis.
Efficacy of Fecal Microbiota Transplantation in the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
Nabil El Hage Chehade, MD, Sara Ghoneim, MD, Sagar Shah, MD, Anastasia Chahine, MD, Fadi H Mourad, MD, Fadi F Francis, MD, David G Binion, MD, Francis A Farraye, MD, MSc, Jana G Hashash, MD, MSc
doi : 10.1093/ibd/izac135
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 808–817
Fecal microbiota transplantation (FMT) has been investigated as a treatment option for patients with inflammatory bowel disease with controversial results.
The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases
Hui Cao, MD, Jun Diao, MMSC, Huosheng Liu, MBBS, Suxian Liu, MD, Jun Liu, MD, Jianye Yuan, PhD, Jiang Lin, PhD
doi : 10.1093/ibd/izac199
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 818–829
Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn’s disease, are characterized by chronic idiopathic inflammation of gastrointestinal tract.
Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases
Rahul S Dalal, MD, MPH, Jordan C Pruce, BS, Jessica R Allegretti, MD, MPH
doi : 10.1093/ibd/izac164
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 830–833
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame
Cristina Bezzio, MD, PhD, Gionata Fiorino, MD, PhD, Davide G Ribaldone, MD, PhD, Alessandro Armuzzi, MD, PhD, Simone Saibeni, MD, PhD, IG-IBD COVID-19 Study Group
doi : 10.1093/ibd/izac173
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 834–836
Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
Hisham S Almomen, MBBS, Badr Al-Bawardy, MD
doi : 10.1093/ibd/izad040
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 837–838
Editorial: Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change
Heidi Glynn, M.Psych, PhD Candidate, Antonina Mikocka-Walus, PhD, Simon R Knowles, PhD
doi : 10.1093/ibd/izac166
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 839–841
Plant-Based Diet Recommended for Inflammatory Bowel Disease
Mitsuro Chiba, MD, PhD, Mihoko Hosoba, MD, PhD, Koko Yamada, RD
doi : 10.1093/ibd/izac279
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages e17–e18,
Reply: Plant-Based Diet Recommended for Inflammatory Bowel Disease
Berkeley N Limketkai, MD, PhD
doi : 10.1093/ibd/izad022
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Page e19
